Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced positive topline full study results from the Phase 3 VISIONARY trial. VOYXACT ® ...

Bupropion conferred modest reductions in cancer-related fatigue compared with placebo, according to results of a randomized ...

Summary: Patients surviving severe traumatic brain injuries often enter states designated as Prolonged Disorders of Consciousness (PDoC) or Locked-In Syndrome (LIS). For decades, standard bedside ...

You'll come for the hands-on tweaking and wealth of features, and quickly forgive some of the workflow issues when you hear ...

The wAIHA market landscape is undergoing a significant evolution after years of dependence on broad immunosuppressive ...

Findings provide mechanistic support for previously reported clinical outcomes of clinical reversal of platinum resistance/refractoriness from ...

Sionna Therapeutics targets cystic fibrosis with novel CFTR/NBD1 stabilization; key 2026 readouts and cash runway to 2028.

(NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced top-line ...

Aging is accompanied by progressive changes in brain structure and function that may affect cognition, emotional regulation, and adaptive behavior. While ...

Data from ongoing Phase 1 study of AX-0810 in healthy volunteers demonstrated dose-dependent target engagement on all key biomarkers in the ...

Sjögren’s disease (SjD) is a chronic, multisystem autoimmune disorder characterised by lymphocytic infiltration of exocrine ...

In adolescents, the most common adverse events (occurring in =5% of ML-004-treated adolescents and at least twice the rate of placebo) were headache (13.7% vs. 3.9%), somnolence (11.8% vs. 0%), nausea ...